JDDG: Journal der Deutschen Dermatologischen Gesellschaft

<jats:title>Summary</jats:title><jats:sec><jats:title>Background and Objectives</jats:title><jats:p>While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce. In this retrospective analysis, we evaluated the combination of BV and RTx in patients with CD30‐positive CTCL.</jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p>We included 14 CD30‐positive CTCL patients from six German cancer centers receiving BV; RTx was initiated within a timeframe of 3 months prior/after BV treatment. RTx was mainly applied as a low‐dose scheme.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Adverse events of any grade occurred in 71% of patients, most commonly peripheral neuropathy, neutropenia, and radiodermatitis. Thirteen patients achieved a complete or partial remission as best overall response, however, 50% of all patients showed disease progression. At a median follow‐up of 14.4 months, median progression‐free survival was 12.0 months, with a 1‐year rate of 34.0%.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The simultaneous or sequential use of RTx during BV treatment was feasible and well tolerated. Future randomized investigations are needed to identify the benefits of this combination treatment regimen as well as adequate dosing of BV and RTx in a prospective manner.</jats:p></jats:sec>

publication_history

received

accepted

published

Cutaneous T‐cell lymphomas‐An update 2021

Hematol Oncol

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up

Ann Oncol

Brentuximab vedotin or physician's choice in CD30‐positive cutaneous T‐cell lymphoma (ALCANZA): an international, open‐label, randomised, phase 3, multicentre trial

Lancet

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T‐cell lymphoma: final data

Blood Adv

Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group

Int J Radiat Oncol Biol Phys

Radiation Therapy for Cutaneous T‐Cell Lymphomas

Dermatol Clin

Cutaneous T‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management

Am J Hematol

Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group

Eur J Cancer

Low dose total skin electron beam therapy for the management of T cell cutaneous lymphomas

Dermatol Ther

Phase Ib study of brentuximab vedotin (BV) with low‐dose total skin electron beam (LD‐TSEB) for treatment of mycosis fungoides (MF) and Sezary syndrome (SS)

J Clin Oncol

Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma

Brentuximab vedotin and AVD followed by involved‐site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Blood

Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy

Case Rep Oncol

Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report

J Hematol

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

Near complete responses to concurrent brentuximab vedotin and ultra‐hypofractionated low‐dose total skin electron beam radiation in advanced cutaneous T‐cell lymphoma

The British journal of dermatology

Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery

Cancer Res

Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma

Adv Radiat Oncol

Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

J Eur Acad Dermatol Venereol

Combination of brentuximab‐vedotin with skin‐directed therapies extends the time to the next therapeutic line in patients with cutaneous T‐cell lymphoma

J Dtsch Dermatol Ges

Real‐World Pattern‐of‐Care Analysis of Primary Cutaneous Lymphomas Radiation Therapy Among European Organisation for Research and Treatment of Cancer Members

While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30-positive cutaneous T-cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce. In this retrospective analysis, we evaluated the combination of BV and RTx in patients with CD30-positive CTCL.
We included 14 CD30-positive CTCL patients from six German cancer centers receiving BV; RTx was initiated within a timeframe of 3 months prior/after BV treatment. RTx was mainly applied as a low-dose scheme.
Adverse events of any grade occurred in 71% of patients, most commonly peripheral neuropathy, neutropenia, and radiodermatitis. Thirteen patients achieved a complete or partial remission as best overall response, however, 50% of all patients showed disease progression. At a median follow-up of 14.4 months, median progression-free survival was 12.0 months, with a 1-year rate of 34.0%.
The simultaneous or sequential use of RTx during BV treatment was feasible and well tolerated. Future randomized investigations are needed to identify the benefits of this combination treatment regimen as well as adequate dosing of BV and RTx in a prospective manner.

Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma - a retrospective multicenter analysis.

Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis

Papers